Alpa IPO Latest News Today

Alpa Laboratories Limited IPO listing date & Info:

Listing On: Monday, August 6, 2007
BSE Script Code: 532878
NSE Symbol: ALPA
Listing in: B1 Group of Securities in BSE
ISIN: INE385I01010
Issue Price: Rs. 68/- Per share (Face Value of Rs. 10/-)

Alpa Laboratories Limited IPO listing date & Info:

  Listing On: Monday, August 6, 2007
  BSE Script Code: 532878
  NSE Symbol: ALPA
  Listing in: B1 Group of Securities in BSE
  ISIN: INE385I01010
  Issue Price: Rs. 68/- Per share (Face Value of Rs. 10/-)

IPO Allotment Status is now available online for Alpa Laboratories Limited.

Alpa Laboratories Limited IPO was closed on July 17, 2007 and was oversubscribed by around 1.11 times (retail 2.14 times).

IPO Allotment Status is now available online for Alpa Laboratories Limited.

Alpa Laboratories Limited IPO was closed on July 17, 2007 and was oversubscribed by around 1.11 times (retail 2.14 times).

Alpa Laboratories Limited is in the business of manufacturing of pharmaceutical formulations. Alpa manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms. It also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands).

Alpa Laboratories Limited is entering the capital markets with an initial public offering, IPO of 95,00,000 Equity Shares, for cash, at a premium to be decided through a 100% Book Built Issue.

The price band for the issue has been fixed at Rs 62/- at lower level and Rs 68/- at upper level for equity share of Rs 10. The issue opens on July 12, 2007, and closes for subscription on July 17, 2007. The equity shares of the company are proposed to be listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Alpa Laboratories Limited is in the business of manufacturing of pharmaceutical formulations. Alpa manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms. It also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands).

Alpa Laboratories Limited is entering the capital markets with an initial public offering, IPO of 95,00,000 Equity Shares, for cash, at a premium to be decided through a 100% Book Built Issue.

The price band for the issue has been fixed at Rs 62/- at lower level and Rs 68/- at upper level for equity share of Rs 10. The issue opens on July 12, 2007, and closes for subscription on July 17, 2007. The equity shares of the company are proposed to be listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Alpa Laboratories Limited is in the business of manufacturing of pharmaceutical formulations. Alpa manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms. It also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands).

Alpa Laboratories Limited is entering the capital markets with an initial public offering, IPO of 95,00,000 Equity Shares, for cash, at a premium to be decided through a 100% Book Built Issue.
 
The price band for the issue has been fixed at Rs 62/- at lower level and Rs 68/- at upper level for equity share of Rs 10. The issue opens on July 12, 2007, and closes for subscription on July 17, 2007. The equity shares of the company are proposed to be listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).